Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials

• J. Hey‐HadaviPfizer (United States)
• Daniel W. SeekinsBristol-Myers Squibb (United States)
• Melissa Palmer
• Denise CoffeyBristol-Myers Squibb (United States)
• John N CaminisSanofi (United States)
• Sandzhar AbdullaevBristol-Myers Squibb (United States)
• Meenal B. PatwardhanAbbVie (United States)
• Haifa TylerOtsuka (United States)
• Ritu RahejaAbbVie (United States)
• Ann Marie Stanley
• Liliam Pineda-SalgadoOtsuka (United States)
• David L. BourdetTheravance Biopharma (United States)
• Raúl J. AndradeCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
• Paul Hideyo HayashiUniversity of North Carolina at Chapel Hill
• Lara Dimick‐SantosUnited States Food and Drug Administration
• Don C. RockeyMedical University of South Carolina
• Alvin EstiloOtsuka (United States)